Literature DB >> 19825188

Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation.

Peter Drakakis1, Dimitris Loutradis, Apostolos Beloukas, Vana Sypsa, Vasiliki Anastasiadou, George Kalofolias, Helen Arabatzi, Erasmia Kiapekou, Konstantinos Stefanidis, Dimitris Paraskevis, Antonis Makrigiannakis, Angelos Hatzakis, Aris Antsaklis.   

Abstract

A simple, safe and cost-effective treatment protocol in ovarian stimulation is of great importance in IVF practice, especially in the case of previous unsuccessful attempts. hCG has been used as a substitute of LH because of the degree of homology between the two hormones. The main aim of this prospective randomized study was to determine, for the first time, whether low dose hCG added to rFSH for ovarian stimulation could produce better results compared to the addition of rLH in women entering IVF-ET, especially in those women that had previous IVF failures. An additional aim was to find an indicator that would allow us to follow-up ovarian stimulation and, possibly, modify it in order to achieve a better IVF outcome; and that indicator may be the cDNA copies of the LH/hCG receptor. Group A patients (n = 58) were administered hCG and Group B rLH (n = 56) in addition to rFSH in the first days of ovarian stimulation. The number of follicles and oocytes and, most importantly, implantation and pregnancy rates were shown to be statistically significantly higher in the hCG group. This study has also determined, for the first time to our best knowledge, m-RNA for LH/hCG receptors in the lymphocytes of peripheral blood 40 h before ovum pick-up. cDNA levels of the hCG receptor after ovarian stimulation were significantly higher among women receiving hCG compared to those receiving LH. In addition, higher levels were encountered among women with pregnancy compared to those without, although this was not statistically significant due to the small number of pregnancies. It seems that hCG permits a highly effective and more stable occupancy of rLH/hCG receptors and gives more follicles and more oocytes. The determination of cDNA copies could be, in the future, a marker during ovulation induction protocols and of course a predictor for the outcome of ART in the special subgroup of patients with previous failures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825188      PMCID: PMC2770481          DOI: 10.1186/1477-7827-7-110

Source DB:  PubMed          Journal:  Reprod Biol Endocrinol        ISSN: 1477-7827            Impact factor:   5.211


  23 in total

Review 1.  Regulation of luteinizing hormone/human chorionic gonadotropin receptor expression: a perspective.

Authors:  K M J Menon; Utpal M Munshi; Christine L Clouser; Anil K Nair
Journal:  Biol Reprod       Date:  2003-12-10       Impact factor: 4.285

Review 2.  Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures.

Authors:  M A Aboulghar; R T Mansour
Journal:  Hum Reprod Update       Date:  2003 May-Jun       Impact factor: 15.610

3.  Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man.

Authors:  S S Yen; O Llerena; B Little; O H Pearson
Journal:  J Clin Endocrinol Metab       Date:  1968-12       Impact factor: 5.958

4.  Revised American Fertility Society classification of endometriosis: 1985.

Authors: 
Journal:  Fertil Steril       Date:  1985-03       Impact factor: 7.329

5.  The role of gonadotropins in the selection of the preovulatory follicle.

Authors:  A J Zeleznik; S G Hillier
Journal:  Clin Obstet Gynecol       Date:  1984-12       Impact factor: 2.190

6.  Expression of mRNA for the LH and FSH receptors in mouse oocytes and preimplantation embryos.

Authors:  E Patsoula; D Loutradis; P Drakakis; K Kallianidis; R Bletsa; S Michalas
Journal:  Reproduction       Date:  2001-03       Impact factor: 3.906

7.  Messenger RNA expression for the follicle-stimulating hormone receptor and luteinizing hormone receptor in human oocytes and preimplantation-stage embryos.

Authors:  Eleni Patsoula; Dimitris Loutradis; Peter Drakakis; Lina Michalas; Ritsa Bletsa; Stylianos Michalas
Journal:  Fertil Steril       Date:  2003-05       Impact factor: 7.329

8.  Luteal phase defects following agonist-triggered ovulation: a patient-dependent response.

Authors:  J C Emperaire; I Parneix; A Ruffie
Journal:  Reprod Biomed Online       Date:  2004-07       Impact factor: 3.828

9.  Functional, structural, and distribution analysis of the chorionic gonadotropin receptor using murine monoclonal antibodies.

Authors:  Ada Funaro; Anna Sapino; Bruna Ferranti; Alberto L Horenstein; Isabella Castellano; Bruno Bagni; Gianni Garotta; Fabio Malavasi
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.

Authors:  Gorka Barrenetxea; Jon Ander Agirregoikoa; María Rosario Jiménez; Arantza Lopez de Larruzea; Teresa Ganzabal; Koldo Carbonero
Journal:  Fertil Steril       Date:  2007-05-29       Impact factor: 7.329

View more
  12 in total

Review 1.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

Review 2.  Kisspeptin signalling and its roles in humans.

Authors:  Eng Loon Tng
Journal:  Singapore Med J       Date:  2015-12       Impact factor: 1.858

3.  Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial.

Authors:  Tahereh Madani; Ladan Mohammadi Yeganeh; Shabnam Khodabakhshi; Mohammad Reza Akhoond; Fatemeh Hasani
Journal:  J Assist Reprod Genet       Date:  2012-09-07       Impact factor: 3.412

4.  Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation.

Authors:  Anne E Chambers; Krishnaveni P Nayini; Walter E Mills; Gillian M Lockwood; Subhasis Banerjee
Journal:  Reprod Biol Endocrinol       Date:  2011-12-23       Impact factor: 5.211

Review 5.  Human Chorionic Gonadotropin: The Pregnancy Hormone and More.

Authors:  Charalampos Theofanakis; Petros Drakakis; Alexandros Besharat; Dimitrios Loutradis
Journal:  Int J Mol Sci       Date:  2017-05-14       Impact factor: 5.923

6.  Randomized, Controlled Pilot Study of Low-Dose Human Chorionic Gonadotropin Administration Beginning From the Early Follicular Phase for Women With Polycystic Ovarian Syndrome Undergoing Ovarian Stimulation Using the Progesterone Protocol.

Authors:  Xiuxian Zhu; Yonglun Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-13       Impact factor: 5.555

7.  A Randomized Controlled Trial on the Efficacy and Safety of Low-Dose hCG in a Short Protocol with GnRH Agonist and Ovarian Stimulation with Recombinant FSH (rFSH) During the Follicular Phase in Infertile Women Undergoing ART.

Authors:  Charalampos Siristatidis; Sofoklis Stavros; Konstantinos Dafopoulos; Theodoros Sergentanis; Ekaterini Domali; Peter Drakakis; Dimitrios Loutradis
Journal:  Reprod Sci       Date:  2021-07-12       Impact factor: 3.060

8.  Addition of low dose hCG to rFSh benefits older women during ovarian stimulation for IVF.

Authors:  Hala Gomaa; Robert F Casper; Navid Esfandiari; Paul Chang; Yaakov Bentov
Journal:  Reprod Biol Endocrinol       Date:  2012-08-06       Impact factor: 5.211

Review 9.  A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology.

Authors:  Diego Ezcurra; Peter Humaidan
Journal:  Reprod Biol Endocrinol       Date:  2014-10-03       Impact factor: 5.211

Review 10.  Past, Present, and Future of Gonadotropin Use in Controlled Ovarian Stimulation During Assisted Reproductive Techniques.

Authors:  Anastasia Prodromidou; Elli Anagnostou; Depy Mavrogianni; Emmanouela Liokari; Evangelia Dimitroulia; Petros Drakakis; Dimitrios Loutradis
Journal:  Cureus       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.